All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Long-term efficacy of deucravacitinib
During the 25th World Congress of Dermatology 2023, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Mark Lebwohl, Mount Sinai, New York, U.S. We asked about the long-term efficacy of deucravacitinib.
Lebwohl discusses the data at 112 weeks of continuous deucravacitinib treatment. He also mentions how, by blocking tyrosine kinase 2, deucravacitinib differs from standard therapies, maintaining a high level of efficacy over time.
At ACR 2022, Phillip Mease reported data from a phase II trial of deucravacitinib in patients with psoriatic arthritis, with a focus on Part B of the trial, which involved treatment up to Week...
The Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Peter van de Kerkhof, Radboud University, Nijmegen, NL. We asked, What’s on the horizon for the treatment of psoriasis?
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox